CLLS (CLLS) Stock Price & Analysis
CLLS (CLLS) fell 2.41% to USD 3.24 as of September 8, 2026 at 09:02 UTC, according to Nexqual real-time market data.
CLLS last closed at USD 3.24; the session ranged USD 3.21–3.41 on volume of 4,834 shares. Market capitalization is —, with a 52-week range of USD 2.35–5.48 (NGM). Source: Nexqual, September 8, 2026 at 09:02 UTC.
Key Statistics (as of September 8, 2026 at 09:02 UTC)
| Price | USD 3.24 |
|---|---|
| Change | ▼ 2.41% (down) |
| Previous Close | USD 3.24 |
| Open | USD 3.24 |
| Day Range | USD 3.21 – 3.41 |
| 52-Week Range | USD 2.35 – 5.48 |
| Volume | 4,834 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (CLLS)
Nexqual's technical model rates CLLS "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 09:02 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.04 (neutral) |
| vs SMA50 | Above (USD 3.02) |
| MACD | 0.1 (positive) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | USD 2.48 | ▲ 1.22% |
| ATRA | Atara Biotherapeutics, Inc. | USD 9.76 | ▲ 3.39% |
| ADAPY | Adaptimmune Therapeutics plc | USD 0.03 | ▲ 8% |
| SGMOQ | Sangamo Therapeutics, Inc. | USD 0.16 | ▼ 5.88% |
| MCRB | Seres Therapeutics, Inc. | USD 5.72 | ▲ 3.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:02 UTC. This page is informational and not investment advice.